Divis Laboratories Ltd, a leading manufacturer and exporter of APIs, intermediates, and nutraceutical ingredients, reported strong financial results for Q2FY26.
Financial Highlights:
- Revenues increased 16.12% year on year to ₹2,715 crore from ₹2,338 crore.
- Total expenses went up 13.12% to ₹1,948 crore from ₹1,722 crore.
- Consolidated net profit surged 35.1% to ₹689 crore from ₹510 crore.
- Earnings per share grew 35.09% to ₹25.95 from ₹19.21.
The company’s significant profit growth was driven by strong demand across global markets, operational efficiencies, and cost control initiatives. Divis also benefited from margin expansion amid competitive pressures in the pharmaceutical ingredients market.
Outlook:
Divis Laboratories is well positioned for continued growth with a robust order book, capacity expansions, and focused R&D investments. The Q2FY26 results reinforce the company’s leadership in the pharmaceutical ingredients space and its strategy for sustainable long-term value creation.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,